


JC10 Rec'd PCT/PTO 2.7 MAY 2005

PCT



Attorney Docket No. Le A 35 944

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#5 PATENT

In re application of: Golz, *et al.*

Serial No.: 10/508,892

Filed: 09/22/2004

For: Diagnostics and Therapeutics for Diseases Associated with Neuropeptide FF Receptor 1 (NPFF1)

**CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)**

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below, with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: **MAY 24 2005**

  
Jill Durante

**MAIL STOP AMENDMENT  
COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450**

**TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))**

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying copy of PTO form 1449.


**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING  
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement transmitted herewith is being filed **before** the mailing date of the first Office Action on the merits.

**FEE PAYMENT**

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.


Respectfully submitted,

  
Susan M. Pellegrino  
Attorney for Applicant(s)  
Bayer Pharmaceuticals Corporation  
400 Morgan Lane  
West Haven, CT 06516

Reg. No.: 48,972

Telephone: (203) 812-6450

Date: **MAY 24 2005**



Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Serial No.	Art Unit	Filing Date	Atty. Docket No.
		10/508,892		09/22/2004	Le A 35 944
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION		Applicant(s)			
		Golz, et al			

U.S. PATENT DOCUMENTS

*	DOCUMENT NO.	DATE (MM/DD/YY)	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

*	DOCUMENT NO.	DATE (DD/MM/YY)	COUNTRY	PRIMARY CLASS	SUB- CLASS	TRANSLATION	
						YES	NO

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

	R1	Lecron, Jean-Claude, "Modulation of Human Lymphocyte Proliferation by FLFQPQRFamide, a FMRFamide-like Peptide with Anti-Opiate Properties," <i>J. of Neuroimmunology</i> , 38: 1-8 (1992).

EXAMINER	DATE CONSIDERED
----------	-----------------

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.